TechBooky AI Assistant
TechBooky AI Assistant
👋 Welcome to TechBooky AI Assistant

I can help with:
🔎 Tech News
🤖 AI Topics
💻 Gadgets
☁️ Cloud
✍️ Guest Posts
📢 Advertising
🔗 Backlinks
📩 Newsletter
  • AI Search
  • Cryptocurrency
  • Earnings
  • Enterprise
  • About TechBooky
  • Submit Article
  • Advertise With TechBooky
  • Contact Us
  • Data Intelligence
TechBooky
  • African
  • AI
  • Metaverse
  • Gadgets
  • Data Intelligence
  • AI Search
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
  • African
  • AI
  • Metaverse
  • Gadgets
  • Data Intelligence
  • AI Search
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
TechBooky
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Home Artificial Intelligence

Multiply Labs Raises $75M To Bring Robots Into Drug Manufacturing

Paul Femi Balo by Paul Femi Balo
October 7, 2026
in Artificial Intelligence, Health, Investment, Startups
Share on FacebookShare on Twitter
Share this story

Send it to someone who should read it.

f Facebook X X in LinkedIn wa WhatsApp tg Telegram @ Email

In Brief
  • Artificial intelligence can help scientists design new medicines, but someone still has to manufacture them safely and consistently.
  • Multiply Labs has raised $75 million to tackle that less glamorous part of the chain, building robotic systems for complex biological therapies.
  • The funding suggests investors see a bottleneck between promising discoveries and treatments that can reach patients at scale.

Artificial intelligence can help scientists design new medicines, but someone still has to manufacture them safely and consistently. Multiply Labs has raised $75 million to tackle that less glamorous part of the chain, building robotic systems for complex biological therapies. The funding suggests investors see a bottleneck between promising discoveries and treatments that can reach patients at scale.

The San Francisco company announced its Series B on October 6, bringing its total funding to more than $100 million since it was founded in 2016. Patrick Soon-Shiong’s NantWorks led the round. New investors include AstraZeneca, Lingotto, Teradyne and Strange Ventures, alongside returning backers such as Lux Capital and Founders Fund. The mix is telling: the company is pitching not just an AI application, but equipment and production capability for drugmakers.

Multiply Labs builds enclosed robotic clusters designed to automate repetitive stages in making biologic medicines. It says manufacturers can install the system alongside existing instruments and validated processes rather than construct a new facility. Its initial focus on cell and gene therapies has expanded toward antibodies, viral vectors and mRNA. Those are areas where small errors, contamination or inconsistent handling can make a batch unusable and delay treatment.

Also worth reading
Morocco ABA Life Signs $40M AI Health Investment Deal Nvidia Wants To Power The World’s Robots As China Buys In Nvidia Unveils Cosmos 3 Edge To Bring Real-Time AI Reasoning To Robots OpenAI’s 2027 Humanoid Demo Could Test AI Beyond the Screen Meta Buys Robotics AI Startup As Big Tech Moves Into Humanoids Sanctuary AI Shows Why Robot Brains May Reach Factories First

The company claims its system can reduce cost per dose by 74 percent and deliver up to 100 times the throughput of manual manufacturing. Those are company figures, not an independent guarantee for every drug or factory. Actual savings depend on the therapy, the production line, regulatory requirements and whether the equipment performs reliably over time. Patients also would not automatically see a price cut simply because one manufacturing step becomes more efficient.

The company says pharmaceutical manufacturers own and operate the clusters themselves, keeping production and data in-house. That model could appeal to drugmakers reluctant to outsource sensitive processes, but it places a high bar on installation, training and support. Multiply Labs says it will use the new funding to grow manufacturing capacity, accelerate product development and expand engineering, regulatory and commercial teams as it moves toward larger-scale deployments.

Much of the conversation about AI in healthcare has centred on the discovery end. New models aimed at drug discovery promise to help researchers identify targets and design experiments faster. Multiply Labs is betting that a faster research pipeline will make the physical production problem more urgent. A molecule proposed by software is not a medicine in a patient’s hand. The difficult work of making it reproducibly, under strict quality controls, may become one of the most important parts of the AI health story.

Related Reading

More contextual TechBooky stories selected from tags, categories and article context.

  • 1688385382185
    39 US AI firms raised $100M+ in 2024: Full list
  • a2bd2f6b13f01e82e392323dd92b4464
    Medikea Raises $1.2M to Expand Hybrid Healthcare in Tanzania
  • miles wang
    OpenAI Researcher's $2B Drug Discovery Plan Shows AI…
  • Startups-struggle-as-investors-cut-funding-scaled
    Nigeria Startup Funding Hits $635 Million, but Four…
  • Physical-Intelligence-founders
    Physical Intelligence's Reported US$1bn Round Shows…
  • rebellions
    Rebellions Secures $400M, Hitting $2.3B Valuation Before IPO
  • Access-to-Markets-2026-800x500
    Four i3 Deals Bring African Health Tech Closer to Patients
  • meta-news
    Vinci Raises $250 Million To Speed Up Chip Design With AI
Keep Reading Smarter

Search TechBooky with AI

Use TechBooky's AI Search to explore the context behind this story and related coverage across the site.

Try AI Search
More On This Topic
Artificial Intelligence Health Investment Startups
Follow TechBooky

Follow TechBooky for more technology stories and newsroom updates.

f Facebook X X in LinkedIn ig Instagram wa WhatsApp

Tags: AI healthcarebiomanufacturingMultiply Labsrobotics
Paul Femi Balo

Paul Femi Balo

Paul Femi Balo is the founder and publisher of TechBooky. He covers artificial intelligence, African technology, digital infrastructure, enterprise technology and the global digital economy.

Search TechBooky
Open TechBooky AI Search Try the AI Assistant

BROWSE BY CATEGORIES

Receive top tech news directly in your inbox

subscription from
Loading

Freshly Squeezed

  • Opinion: Your Private Chats Should Not Become AI Training Ground November 22, 2026
  • AI Weapons Talks End Without Binding Rules as Geneva Misses Treaty Mandate November 22, 2026
  • Signal Blocks Siri and Gemini From Reading Private Chats November 22, 2026
  • Trump Threatens Tax on US Firms Building AI Data Centres Abroad November 21, 2026
  • OpenAI Tests Whether AI Can Pick Promising Drug Candidates November 21, 2026
  • Anthropic Mathematician Claims Claude Helped Prove Riemann Hypothesis November 21, 2026
  • Nvidia Accounting Practices Under SEC Scrutiny, Reuters Says November 21, 2026
  • White House Names Kirsten Davies as Cyber Director Amid Outage Concerns November 20, 2026
  • Apple Job Listings Point to AI Agent That Can Work Across Apps November 20, 2026
  • Anthropic IPO Shares Give Back Early Gains as AI Stocks Sell Off November 20, 2026
  • Nigeria Selects Eight Startups for iDICE Growth Lab With Up to $100K Each November 20, 2026
  • AWS Lambda Doubles On-Demand Event Function Limit to 30 Minutes November 20, 2026

Browse Archives

November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
« Oct    

Quick Links

  • About TechBooky
  • Advertise With TechBooky
  • Contact us
  • Submit Article
  • Privacy Policy
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
  • AI
  • Data Intelligence
  • AI Search
  • African
  • Gadgets

© 2025 Designed By TechBooky Elite

Discover more from TechBooky

Subscribe now to keep reading and get access to the full archive.

Continue reading

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.